卵巢癌ZNF711基因的表达及其预后价值  

Expression of ZNF711 gene in ovarian cancer and its prognostic value

作　　者：张丽 王艺璇 张韶华 王赞宏 Zhang Li;Wang Yixuan;Zhang Shaohua;Wang Zanhong(Department of Obstetrics and Gynecology,the Third Hospital of Shanxi Medical University,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital,Taiyuan 030032,China)

机构地区：[1]山西白求恩医院山西医学科学院同济山西医院山西医科大学第三医院妇产科,太原030032

出　　处：《肿瘤研究与临床》2025年第3期211-217,共7页Cancer Research and Clinic

基　　金：山西省科技成果转化引导专项二批项目(201604D132043);山西省基础研究计划(202103021224352);山西省中央引导地方项目(YDZJSX2022B012)。

摘　　要：目的探讨ZNF711在卵巢癌中的表达情况及其与预后的关系和可能作用。方法回顾性队列研究。利用GEPIA数据库(数据更新时间2020年10月)分析426例卵巢癌样本和88例正常卵巢组织样本ZNF711 mRNA的表达情况;从GEPIA数据库筛选出424例卵巢癌患者,从Kaplan⁃Meier Plotter数据库筛选的373例卵巢癌患者,以两数据库卵巢癌样本ZNF711 mRNA中位相对表达量分别分组,比较同一数据库两组总生存情况;利用cBioPortal数据库(数据更新时间为2023年9月)筛选癌症基因组图谱(TCGA)数据库中489例卵巢浆液性囊腺瘤样本前30个卵巢癌组织中与ZNF711共表达的基因;将此30个共表达基因导入David数据库(数据更新时间为2023年10月),进行基因本体(GO)及京都基因与基因组百科全书(KEGG)富集分析。基于TIMER数据库基因模块分析卵巢癌中ZNF711的表达与6种免疫细胞浸润的相关性。收集2012年1月至2017年12月在山西白求恩医院手术治疗的178例卵巢癌患者卵巢癌组织和同期因子宫肌瘤行全子宫+双侧附件切除术的53例患者正常卵巢组织。采用免疫组织化学法检测卵巢组织ZNF711蛋白的表达,按阳性细胞比例评分与染色强度评分的乘积计算免疫组织化学评分,范围0~12分,按是否≤8分判定ZNF711蛋白低表达和高表达。比较ZNF711蛋白高、低表达组患者总生存,以及不同临床病理特征分层间ZNF711蛋白高、低表达患者分布;采用单因素和多因素Cox比例风险模型分析卵巢癌患者总生存的影响因素。结果GEPIA数据库426例卵巢癌组织样本和88例正常卵巢组织样本中,ZNF711 mRNA在卵巢癌组织中相对表达量低于正常卵巢组织,差异有统计学意义(P<0.05)。GEPIA数据库和Kaplan⁃Meier Plotter数据库卵巢癌组织ZNF711 mRNA中位相对表达量分别为8.46、8.57,GEPIA数据库:ZNF711高表达组(212例)总生存较ZNF711低表达组(212例)好(P=0.010),Kaplan⁃Meier Plotter数据库ZNF711高表�Objective To investigate the expression of ZNF711 in ovarian cancer and its relationship with prognosis and its possible role.Methods A retrospective cohort study was conducted.The GEPIA database(data updated in October 2020)was used to analyze the expression of ZNF711 mRNA in 426 ovarian cancer samples and 88 normal ovarian tissue samples;424 ovarian cancer patients were screened from the GEPIA database,and 373 ovarian cancer patients were screened from the Kaplan-Meier Plotter database.The patients were grouped according to the median relative expression levels of ZNF711 mRNA in ovarian cancer samples from the two databases,and the overall survival of the two groups in the same database was compared.The cBioPortal database(data updated in September 2023)was used to screen for the top 30 genes co-expressed with ZNF711 in ovarian cancer tissues from 489 ovarian serous cystadenoma samples in The Cancer Genome Atlas(TCGA)database;these 30 co-expressed genes were imported into the David database(data updated in October 2023)for Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)enrichment analyses.The correlation between ZNF711 expression and 6 types of immune cell infiltration in ovarian cancer was analyzed based on the TIMER database gene module.The ovarian cancer tissues from 178 ovarian cancer patients who underwent surgical treatment at Shanxi Bethune Hospital from January 2012 to December 2017,as well as the normal ovarian tissues from 53 patients who underwent total hysterectomy and bilateral adnexectomy for uterine fibroids during the same period were collected.Immunohistochemistry was used to detect the expression of ZNF711 protein in ovarian tissues.The immunohistochemical score was calculated by multiplying the positive cell ratio score and the staining intensity score,ranging from 0 to 12 points,and low or high expression of ZNF711 protein was determined by whether it was≤8 points.The overall survival of patients with high and low expression of ZNF711 protein,as well as the distribution

关 键 词：卵巢肿瘤 ZNF711蛋白 肿瘤微环境 免疫细胞 预后 

分 类 号：R737.31[医药卫生—肿瘤]